📊 IVF Key Takeaways
Is INVO Fertility, Inc. (IVF) a Good Investment?
INVO Fertility is in critical financial distress with a fundamentally broken business model. The company generates only $6.8M in annual revenue while operating at a -340.9% net margin and burning $7.1M in free cash flow, leaving approximately 3-4 months of cash runway at current burn rates. The 4% gross margin indicates the core business cannot generate profitability at any scale, making revenue growth insufficient to address structural losses.
INVO Fertility's fundamentals are extremely weak, with flat revenue, very poor gross profitability, and operating losses that exceed annual sales. The balance sheet shows severe near-term liquidity stress, and the company's cash burn is far too high relative to its cash position, making financing risk and dilution risk major concerns.
INVO Fertility, Inc. Key Strengths (IVF)
- Modest revenue growth of 4.7% YoY shows some market demand
- Debt-to-equity ratio of 0.12x indicates moderate financial leverage
- Reduction in net losses year-over-year (improved 7.2%) suggests cost controls in place
- Revenue was roughly stable year over year, indicating the business has at least maintained its current scale
- Debt levels are not the primary balance-sheet problem, with debt/equity of 0.34x
- Stockholders' equity remains positive at $5.85M, so the company is not yet balance-sheet insolvent
IVF Stock Risks: INVO Fertility, Inc. Investment Risks
- Critical liquidity crisis with current ratio of 0.27x (severe working capital deficit)
- Unsustainable cash burn of $7.1M annually versus $6.8M revenue (negative operating cash flow)
- Deeply unprofitable business model with -105.8% operating margin and 4% gross margin indicating broken unit economics
- Minimal cash reserves ($2.1M) provide insufficient runway relative to burn rate
- No insider buying activity in past 90 days signals zero management confidence
- Company likely requires immediate capital infusion or faces insolvency within months
- Gross margin of 5.2% and operating margin of -110.8% indicate an unsustainably weak business model at current scale
- Current ratio of 0.12x, quick ratio of 0.10x, and cash of just $355.89K point to severe liquidity risk
- Operating cash flow of -$7.04M and free cash flow of -$7.07M imply continued external funding needs
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Gross margin improvement (critical that it exceeds 25%+ for viability)
- Operating cash flow trend and path to breakeven
- Any announcements of capital raises, debt restructuring, or strategic alternatives
- Gross margin and operating loss trend
- Cash balance relative to quarterly operating cash burn
INVO Fertility, Inc. (IVF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IVF Profit Margin, ROE & Profitability Analysis
IVF vs Healthcare Sector: How INVO Fertility, Inc. Compares
How INVO Fertility, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INVO Fertility, Inc. Stock Overvalued? IVF Valuation Analysis 2026
Based on fundamental analysis, INVO Fertility, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INVO Fertility, Inc. Balance Sheet: IVF Debt, Cash & Liquidity
IVF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: INVO Fertility, Inc.'s revenue has grown significantly by 58% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3,782.65 indicates the company is currently unprofitable.
IVF Revenue Growth, EPS Growth & YoY Performance
IVF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $1.6M | -$1.6M | $-7.55 |
| Q3 2024 | $974.9K | -$1.2M | $-0.42 |
| Q2 2024 | $315.9K | -$1.6M | $-0.62 |
| Q1 2024 | $348.0K | -$1.6M | $-0.42 |
| Q3 2023 | $235.3K | -$1.2M | $-0.70 |
| Q2 2023 | $146.1K | -$2.2M | $-3.06 |
| Q1 2023 | $162.6K | -$2.6M | $-0.20 |
| Q3 2022 | $218.9K | -$2.2M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INVO Fertility, Inc. Dividends, Buybacks & Capital Allocation
IVF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for INVO Fertility, Inc. (CIK: 0001417926)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IVF
What is the AI rating for IVF?
INVO Fertility, Inc. (IVF) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IVF's key strengths?
Claude: Modest revenue growth of 4.7% YoY shows some market demand. Debt-to-equity ratio of 0.12x indicates moderate financial leverage. ChatGPT: Revenue was roughly stable year over year, indicating the business has at least maintained its current scale. Debt levels are not the primary balance-sheet problem, with debt/equity of 0.34x.
What are the risks of investing in IVF?
Claude: Critical liquidity crisis with current ratio of 0.27x (severe working capital deficit). Unsustainable cash burn of $7.1M annually versus $6.8M revenue (negative operating cash flow). ChatGPT: Gross margin of 5.2% and operating margin of -110.8% indicate an unsustainably weak business model at current scale. Current ratio of 0.12x, quick ratio of 0.10x, and cash of just $355.89K point to severe liquidity risk.
What is IVF's revenue and growth?
INVO Fertility, Inc. reported revenue of $6.8M.
Does IVF pay dividends?
INVO Fertility, Inc. does not currently pay dividends.
Where can I find IVF SEC filings?
Official SEC filings for INVO Fertility, Inc. (CIK: 0001417926) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IVF's EPS?
INVO Fertility, Inc. has a diluted EPS of $-214.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IVF's fundamental grade?
Based on our AI fundamental analysis in June 2026, INVO Fertility, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IVF stock overvalued or undervalued?
Valuation metrics for IVF: ROE of -322.8% (sector avg: 15%), net margin of -340.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IVF's AI grade for 2026?
Our dual AI analysis gives INVO Fertility, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IVF's free cash flow?
INVO Fertility, Inc.'s operating cash flow is $-7.0M, with capital expenditures of $43.4K. FCF margin is -103.2%.
How does IVF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -340.9% (avg: 12%), ROE -322.8% (avg: 15%), current ratio 0.27 (avg: 2).